Researched and relatable, science-driven and social, you're an extroverted expert. Ablynx has partnered with Syneos Health to fill direct hire positions for their first US Medical Science Liaison team.
Founded in 2001, Ablynx is a biopharmaceutical company engaged in the development of Nanobodies , a novel class of therapeutic proteins.
Headquartered in Belgium, our client has more than 45 proprietary and partnered programs in development in various therapeutic areas including inflammation, hematology, immuno-oncology, oncology and respiratory disease. Ablynx is currently running a number of promising Phase II trials (RSV, RA, SLE) and expects to launch its first product, caplacizumab, focused on acquired Thrombotic Thrombocytopenic Purpura (aTTP) in 2018 in European markets and in 2019 in US.
Our client aims to utilize its unique Nanobody technology to develop therapeutics in areas of high unmet medical need where Nanobodies offer a clear promotable advantage over existing products and technologies. This is demonstrated with the continued investment in multiple internal R&D programs and the continuation of key strategic partnerships with major pharmaceutical organizations.
At present, Ablynx has over 400 staff members with the majority located in their Belgium Headquarters. Currently Ablynx is investing in and building their medical and commercial organizations within EU and US to support the launch of caplacizumab. Ablynx has established highly innovative, world-class expertise and capabilities and is very excited about its future, potentially as part of the Sanofi family that will further increase the range of opportunities for their staff to unlock the power of the Nanobody platform.